NCT00064142View on ClinicalTrials.gov

Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

December 31, 2006

Conditions
AIDS-related Kaposi SarcomaRecurrent Kaposi Sarcoma
Interventions
DRUG

halofuginone hydrobromide

Applied topically

OTHER

placebo

Applied topically

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

20850

AIDS - Associated Malignancies Clinical Trials Consortium, Rockville

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00064142 - Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma | Biotech Hunter | Biotech Hunter